Gabapentin Tablet, Film Coated
Product Images NDC 70518-4532

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4532). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 600mg 70518 4532 01)

This is a description of a Gabapentin tablet with a strength of 600 mg. It comes in a package for one tablet, and the NDC number is 70518-4532-01. The tablet is oval, white, and the usual dosage information can be found in the insert. The medication is repackaged by RemedyRepack Inc. in Indiana, PA. The manufacturer is Granules located in Chantilly, VA. The text also mentions storage instructions to keep the medication out of reach of children and store between 20-25°C with excursions permitted to 15-30°C.*

FDA Label Image

Remedy_label (Remedy Label)

Description: A box of 100 Gabapentin tablets, each containing 600 mg. The tablets are oval, white, and stored at temperatures between 20-25°C. Manufactured by Granules in Chantilly, VA, the medication is repackaged by RemedyRepack Inc. It is important to keep all medications out of the reach of children. See insert for usual dosage information.*

FDA Label Image

Equation (Equation)

This text provides a formula for estimating creatinine clearance, a measure of kidney function. The formula requires the age of the patient in years, weight in kilograms (1.23 kg for female patients), and serum creatinine level in mg/dL. The formula is: cLer = 140 - (age in years) x weight (in kg) x 0.85 (for female patients) / 72 x serum creatinine (mg/dL).*

FDA Label Image

Fig-1 (Fig 1)

FDA Label Image

Fig-2 (Fig 2)

FDA Label Image

Fig-3 (Fig 3)

This excerpt provides data on the proportion of responders in controlled post-herpetic neuralgia (PHN) studies, specifically highlighting the percentage of patients with more than a 50% reduction in pain score at the endpoint. Study 1 had 29% responders while Study 2 had 31%. The data compares the effect of PBO (placebo), GBP 300, GBP 1800, and GBP 2400.*

FDA Label Image

Fig-4 (Fig 4)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.